- Home
- IVVD vs ADAG Comparison
IVVD vs ADAG Comparison
Compare IVVD & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- ADAG
- Stock Information
- Founded
- IVVD 2020
- ADAG 2011
- Country
- IVVD United States
- ADAG China
- Employees
- IVVD N/A
- ADAG N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- IVVD Health Care
- ADAG Health Care
- Exchange
- IVVD Nasdaq
- ADAG Nasdaq
- Market Cap
- IVVD 69.0M
- ADAG 76.3M
- IPO Year
- IVVD 2021
- ADAG 2021
- Fundamental
- Price
- IVVD $0.75
- ADAG $1.90
- Analyst Decision
- IVVD Strong Buy
- ADAG Strong Buy
- Analyst Count
- IVVD 3
- ADAG 1
- Target Price
- IVVD $5.85
- ADAG $8.00
- AVG Volume (30 Days)
- IVVD 1.8M
- ADAG 75.4K
- Earning Date
- IVVD 08-13-2025
- ADAG 07-24-2025
- Dividend Yield
- IVVD N/A
- ADAG N/A
- EPS Growth
- IVVD N/A
- ADAG N/A
- EPS
- IVVD N/A
- ADAG N/A
- Revenue
- IVVD $36,688,000.00
- ADAG $103,204.00
- Revenue This Year
- IVVD $446.60
- ADAG $6,488.89
- Revenue Next Year
- IVVD $112.63
- ADAG $57.50
- P/E Ratio
- IVVD N/A
- ADAG N/A
- Revenue Growth
- IVVD N/A
- ADAG N/A
- 52 Week Low
- IVVD $0.35
- ADAG $1.33
- 52 Week High
- IVVD $2.74
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- IVVD 43.27
- ADAG 52.47
- Support Level
- IVVD $0.70
- ADAG $1.73
- Resistance Level
- IVVD $1.03
- ADAG $2.02
- Average True Range (ATR)
- IVVD 0.07
- ADAG 0.15
- MACD
- IVVD -0.03
- ADAG -0.01
- Stochastic Oscillator
- IVVD 12.75
- ADAG 42.50
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.